**Essential hypertension is associated with changes in gut microbial metabolic pathways: A multi-site analysis of ambulatory blood pressure**

**Short title:** Human hypertensive gut bacteriome

Michael Nakai, BSc(Hons)¹*; Rosilene V Ribeiro, PhD²,³*; Bruce R. Stevens, PhD⁴; Paul Gill, PhD⁵; Rikeish R. Muralitharan, B. Med Sci(Hons)¹,⁶; Stephanie Yiallourou, PhD⁷; Jane Muir, PhD⁵; Melinda Carrington, PhD⁷; Geoffrey A. Head, PhD⁸,⁹; David M. Kaye, MD, PhD¹⁰,¹¹,¹²; Francine Z. Marques, PhD¹,¹⁰#

¹Hypertension Research Laboratory, School of Biological Sciences, Monash University, Melbourne, Australia; ²Charles Perkins Centre, University of Sydney, Sydney, Australia; Department of Physiology, Monash University, Melbourne, Australia; ³School of Life and Environmental Sciences, Faculty of Science, The University of Sydney, Sydney, Australia; ⁴University of Florida, College of Medicine, Department of Physiology and Functional Genomics, Gainesville, FL, USA; ⁵Department of Gastroenterology, Monash University, Melbourne, Australia; ⁶Institute for Medical Research, Ministry of Health Malaysia, Kuala Lumpur, Malaysia; ⁷Preclinical Disease and Prevention, Baker Heart and Diabetes Institute, Melbourne, Australia; ⁸Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; ⁹Department of Pharmacology, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia; ¹⁰Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia; ¹¹Department of Cardiology, Alfred Hospital, Melbourne, Australia; ¹²Central Clinical School, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia;

*Authors contributed equally as first authors

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
#Correspondence to: Associate Professor Francine Marques. 25 Rainforest Walk, Clayton, Monash University, VIC Australia 3800. E: francine.marques@baker.edu.au, francine.marques@monash.edu
Abstract

Aims: Recent evidence supports a role for the gut microbiota in hypertension, but whether ambulatory blood pressure (BP) is associated with gut microbiota and their metabolites remains unclear. Here we characterised the function of the gut microbiota, their metabolites and receptors in untreated human hypertensive participants in metropolitan and regional areas of Australia.

Methods and Results: Ambulatory BP, faecal microbiome DNA 16S rRNA gene sequencing, plasma and faecal metabolites called short-chain fatty acid (SCFAs), and expression of their receptors were analysed in 70 untreated and otherwise healthy participants from metropolitan and regional communities. Based on machine-learning multivariate covariance analyses of de-noised amplicon sequence variant (ASV) prevalence data, we determined that there were no significant differences in gut microbiome community α- and β-diversity metrics between normotensives versus essential, white coat or masked hypertensives. However, select taxa were specific to these groups, notably Acidaminococcus spp. in essential hypertensives, and Ruminococcus spp. and Coprobacillus in normotensive subjects. Importantly, normotensive and essential hypertensive cohorts could be differentiated based on gut microbiome gene pathways and metabolites. Specifically, hypertensive participants exhibited higher plasma acetate and butyrate, but their immune cells expressed reduced levels of SCFA-activated G-protein coupled receptor 43 (GPR43).

Conclusions: While gut microbial diversity did not change in essential hypertension, there was a significant shift in microbial gene pathways, and an increase in the circulating levels of the SCFAs acetate and butyrate. Hypertensive subjects, however, had lower levels of the SCFA-sensing receptor GPR43, putatively blunting their response to BP-lowering metabolites.
**Keywords:** Hypertension, ambulatory blood pressure, gut microbiota, gut microbiome, gut metabolites, metabolites, short-chain fatty acids.
**Introduction**

Lifestyle and environmental factors are well-established contributors to increased blood pressure (BP). The gut microbiota, the community of microorganisms that inhabit our small and large intestines, is a newly described risk factor for the development of hypertension.\(^1,^2\) Importantly, increasing evidence using faecal microbiota transplants (FMTs) to germ-free animals supports that the gut microbiota is not merely associated with experimental and essential hypertension, but it drives an increase in BP.\(^3^\text{-}^5\) While some studies have explored the association between essential hypertension and the gut microbiota,\(^4,^6^\text{-}^13\) a major limitation has been the use of self-reported hypertension or office BP, which do not allow for distinction between types of hypertension and decrease the power of studies.\(^1\) All but one study also included patients using a varied range of BP-lowering medications, but each of these medications on their own have been reported to affect the gut microbiota.\(^14,^15\)

A major modulator of the gut microbiota is diet, which can alter the microbiota in as little as a few days.\(^16\) Dietary fibre, in particular soluble fibre and resistant starches (also known as prebiotics), are particularly important as they feed commensal bacteria. Fibre is also important for BP control: in a meta-analysis and a prospective study that involved 388,000 participants followed-up for approximately 9 years, fibre intake was associated with lower risk of both cardiovascular and all-cause death, and lower systolic BP (SBP).\(^17\) This was validated by a more recent study, which identified that fibre intake is an underlying factor for mortality, driven by BP.\(^18\) Fermentation of fibre by gut bacteria results in the release of short-chain fatty acids (SCFAs). SCFAs, such as acetate, propionate and butyrate, are able to lower BP in experimental models of hypertension.\(^3,^8,^19,^20\) Yet, a lack of consistency in SCFA levels still exists across studies in essential hypertension and its association with BP.\(^12,^26\) This may be due to the volatile characteristic of these metabolites, making them
challenging to quantify, as well as differences in colonic (i.e., produced), faecal (i.e., excreted) and circulatory (i.e., absorbed) levels.27

Here we aimed to characterise the gut bacteriome, their function and levels of SCFAs in participants will well-characterised BP. Our study addresses the following limitations in our field: it is the first multi-site gut microbiota study which analysed samples from both male and female participants from regional and metropolitan areas, diagnosed using ambulatory BP monitoring (ABPM). As such, we provide the gut bacteriome of patients with essential, masked and white coat hypertension. Importantly, all participants included were not receiving any BP-lowering medication. We also determined the impact of their diet on the gut bacteriome and associated circulating and faecal levels of SCFAs and SCFA-sensing receptors.

**Methods**

**Participants and recruitment**

Seventy participants were recruited from the community in metropolitan (n=41 Baker Institute and Alfred Hospital, Melbourne) and regional (n=36 Shepparton) areas (Figure S1). Inclusion criteria were: aged 40-70 years, either sex, body mass index (BMI) 18.5-30 kg/m², and not using BP-lowering medication. Exclusion criteria included gastrointestinal disease (including history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis or other malabsorption disorder), diabetes (type 1 and 2), chronic kidney disease, probiotics or antibiotics use in the past 3 months. Three participants were excluded due to high BMI and four were excluded due to incomplete 24-hour BP measurements. After exclusions, a total of 70 participants remained: 40 in the metropolitan clinics and 30 in the regional clinic (Figure S1). This study complied with the Declaration of
Helsinki, and was approved by the human research ethics committee of the Alfred Hospital. All participants provided informed consent. The study is registered in the Australian New Zealand Clinical Trials Registry under ACTRN12620000958987.

**Blood pressure measurement and hypertension diagnosis**

Office BP was measured using an automatic BP monitor (Omron) after the participant had been seated for at least 5 minutes with both feet flat on the floor, legs uncrossed and upper arm relaxed. Two measurements were taken 1 minute apart, and if systolic BP was >15 mmHg apart of diastolic BP >10 mmHg apart a third measurement was performed and averaged. Participants were then fitted with a calibrated ABPM device (AND or SpaceLabs) for 24-hours and given clear instructions of how to operate the device and when to remove it. Hypertension was diagnosed using the European guidelines.21

**Food frequency questionnaire**

Dietary intake over a period of 12 months was assessed using the Dietary Questionnaire for Epidemiological Studies (DQES) version 3.2, a self-administered and validated food frequency questionnaire (FFQ), developed by the Cancer Council Victoria that reflects dietary intake of the Australian population.22 Dietary intake estimates of 98 nutrients were derived from two Australian databases, AUSNUT 200723 and NUTTAB 2010.24 Since data on fibre subtypes (insoluble fibre, soluble fibre and resistant starch) are not provided by DQES v3.1, we have followed the protocol previously described25 to obtain those estimates. This method involves calculating the amount of total fibre and fibre subtypes for each single food using the following sources: (1) latest dietary fibre values found on the AUSNUT 2011-13 database;26 (2) food industry provided dietary fibre composition data published by FSANZ;27 and (3) the published dietary fibre data by the FSANZ in “Composition of Foods”, Australia, 1989.28
Participants’ diet quality was measured by comparing their intake (according to age and sex) with the Dietary Guidelines for Australian (DGA) recommendations using the Australian Dietary Guideline Index (DGI-2013). The DGI-2013 includes ten components in total: six core-food components reflecting adequacy, quality and variety of intake within the ADG core food groups (vegetables, fruit, grains, lean meats and alternatives, and dairy and alternatives), one reflecting adequacy of fluid intake, and three noncore food groups (unsaturated spreads or oils, discretionary items and alcohol) reflecting compliance with guidelines to moderate or limit intake. The quality of grain (prefer wholegrain), dairy foods (prefer reduced-fat) and fluid intake (prefer water) was also assessed to reflect the recommendations set by ADG. Total beverage intake consisted of water, fruit juice, tea, coffee, milk and milk-based beverages. Altogether, a maximum of 120 points could be achieved if all ADG recommendations were met (i.e. high diet quality).

Faecal DNA extraction, library preparation and sequencing

Our study followed guidelines for gut microbiota studies in hypertension. Stool samples were collected by participants at home in empty tubes (for SCFA determination) or tubes containing RNAlater (Thermo Scientific, previously shown to preserve bacterial DNA) for microbial DNA extraction. Tubes were brought to the clinics immediately or stored at -20°C for less than 24-hours and then brought to the clinics, where they were stored at -80°C until further processing. DNA was extracted using the DNeasy PowerSoil DNA isolation kit (Qiagen). The V4-V5 region of the bacterial 16S rRNA was amplified by PCR using 20ng of DNA, Platinum Hot Start PCR master mix (ThermoFisher Scientific), 515F and 926R primers (Bioneer) and methods previously described in a Veriti Thermal Cycler (ThermoFisher Scientific). The quality and quantity of the PCR product was assessed in a Qubit (ThermoFisher Scientific), and 240ng of PCR product per sample were pooled and cleaned using the PureLink PCR Purification kit (ThermoFisher Scientific). The product was
then sequenced in a Illumina MiSeq sequencer (300 bp paired-end reads). To increase the reproducibility of the findings, all samples were independently sequenced twice.

**Bioinformatics**

Sequence reads from samples were first analysed using the QIIME2 framework.\(^{36}\) Forward and reverse reads were first truncated at base number 243 for forward reads and base number 224 for reverse reads, then were denoised, merged, and chimera filtered using the DADA2 plugin,\(^{37}\) resulting in an amplicon sequence variant (ASV) table (via q2-dada2) with resolution at the single nucleotide level. A phylogeny was then created using fasttree2\(^ {38}\) from mafft-aligned\(^ {39}\) ASVs, and were then subsampled without replacement to 29,000 reads per sample (via q2-alignment and q2-phylogeny). Both \(\alpha\) and \(\beta\) diversity metrics were generated from the rarefied samples (via q2-diversity), including unweighted and weighted Unifrac metrics along with associated Principle Coordinate Analysis (PCoA) distance tables. Taxonomic assignment used a naïve Bayes classifier to label ASVs (via q2-feature-classifier\(^ {40}\)), trained against the GreenGenes\(^ {41}\) (version 13_8) 99% OTU reference sequences specific for bacterial V4-V5 rRNA regions. Categorical sample metadata predictions were attempted on the rarefied samples using the q2-sample-classifier plugin.\(^ {42}\)

Separately, the OTU table output from the QIIME2 framework was converted to predicted gene abundances on the Pipihillin server.\(^ {43}\) The resulting hypothesised gene abundances were then imported into R (version 4.0.2) using the package phyloseq\(^ {44}\) and transferred through the R package PIME\(^ {45}\) to capture gene abundance differences only at high sample prevalence levels. Effect sizes for genes were generated when PIME-filtered tables were passed onto ALDEEx2 for a differential abundance analysis to compare selected categorical variables in the metadata.\(^ {46}\)

**Short-chain fatty acids measurement**
Plasma SCFAs were measured in 200 µL and faecal SCFAs were measured from 1 g of faecal sample, all in triplicates, as previously published. Heptanoic acid was used as an internal standard. Samples were analysed using an Agilent GC6890 coupled to a flame-ionisation detector (FID), with helium used as the carrier gas. An Agilent FFAP column (30 m x 0.53 mM (internal diameter) x 1.00 µM (film thickness)) was installed for analysis. A splitless injection technique was used, with 0.2 µL of sample injected. A constant flow rate of 4.0 mL/min was used on the column. Upon injection, the oven was initially held at 90 °C for 1 minute, then raised to 190 °C at 20 °C/min and held for 3 minutes. A coefficient of variation of <10% within triplicate samples was used as a quality control measure.

**Blood expression of SCFA receptors and transporters**

We have previously shown in animal models that all 3 main SCFA-sensing receptors GPR41 (FFAR3), GPR43 (FFAR2) and GPR109A (HCAR2) have a role in cardiovascular dysfunction. These receptors are highly expressed in immune cells. To determine whether hypertensive patients had a deficiency in sensing these receptors, we quantified their levels in white blood cells from the participants with the highest (n=22 hypertensives) and lowest BP (n=25). Blood RNA was extracted using the Red Blood Cell Lysis Buffer (ThermoFisher Scientific) and RNeasy Mini kit (Qiagen). RNA was quantified in a Nanodrop Spectrophotometer and first-strand complementary synthesis reaction (cDNA) was made using the SuperScript™ IV VILO™ Master Mix with ezDNase™ Enzyme (ThermoFisher Scientific). TaqMan assays (Table S1) and the TaqMan Advanced Fast Master Mix were used in a QuantStudio 6 Flex Real-Time PCR (qPCR) system (all ThermoFisher Scientific). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and β-actin (ACTB) were used as housekeeping genes. All expression experiments were run in duplicates and significance was assessed by $2^{-\Delta\Delta C_{T}}$ method.
Statistical analyses

Data were analysed blind. GraphPad Prism (version 8) package was used for statistical analysis and graphing. Results were tested for outliers using the Robust regression and outlier removal (ROUT) method and for normal distribution using the D'Agostino & Pearson tests. Non-parametric tests were used in case of non-normally distributed data. An $F$ test was used to verify similar variance between groups. Two-tail independent sample t-tests (with Welch’s correction in the case of different variance) were used to compare the data between 2 groups. Correlations were performed using Pearson’s or Spearman’s correlation coefficients. Further analyses were conducted using step-wise multiple linear regression models with clinical (age, sex, body mass index, recruitment centre) variables as independent parameters (criteria of F-entry probability: 0.15, removal: 0.20) in Statistical package SPSS for Windows (release 25). Values are presented as mean±SEM, and those with a $P<0.05$ considered significant.

Results

Participants’ characteristics

A total of 70 participants were included in this study (Table 1). Based on ABPM, we identified that 33% of participants had hypertension. Four percent had white coat and 19% were masked hypertensives. Hypertensive patients had a similar age and body mass index (BMI) compared to normotensive controls, but there were sex differences between hypertensive, masked hypertensive and normotensive participants. As expected hypertensive and masked hypertensive participants also had higher ABPM, while white coat hypertensive participants had high office BP, but not ABPM. One participant was excluded due to low
number of microbiome sequencing reads, resulting in a total of 69 participants included in the sequencing analyses below.

**Dietary food intake**

There was no difference between total fibre, resistant starches, insoluble and soluble fibre levels between normotensive and hypertensive participants, nor for different types of food individually that contribute towards the total fibre intake (e.g., nuts, legumes, grains) (Table S2). There was also no statistically significant difference in Australian dietary score between normotensive (60.2±1.1) and hypertensive participants (58.5±1.6, \( P = 0.358 \)).

**Gut microbiome**

In total, over 4.3 million reads were denoised, merged, and survived chimera filtering, a survival rate of 43% with read counts averaging 63,000 reads per sample. Rarefaction of samples to 29,000 reads showed consistent and plateauing diversity metrics across samples (Figure S2), but caused the loss of data from one participant. We quantified two commonly used metrics for gut microbiome studies, \( \alpha \)- (i.e., a within sample metrics) and \( \beta \)-diversity (i.e., a between samples metrics). We found no association between 5 measurements of \( \alpha \)-diversity and essential hypertension (Table S3), masked hypertension or white coat hypertension in t-tests nor using machine learning algorithms (data not shown). We identified similar results when we studied \( \beta \)-diversity: there was no difference between normotensive controls and essential hypertensive (Figure S3), masked hypertensive (Figure S4) and white coat hypertensive (Figure S5) participants. There was also no \( \beta \)-diversity difference between clinics, sex, age, BMI, fibre intake or diet score (Figure S6). However, some specific taxa were still more prevalent in hypertensive groups or normotensive controls (Figure 1). We then performed validation analyses adjusted by sex as the only demographic that was different across groups, as well as correlations between the microbiome, SBP and DBP.
We identified that essential hypertensive subjects had higher levels of Acidaminococcus spp. and lower levels of Ruminococcus spp. and Coprobacillus spp.; masked hypertensives had higher lower levels of Ruminococcus spp.; and white coat hypertensives had higher levels of Clostridium perfringens, Bacteroides spp. and Sphingobacteriales (Figures 1 and S7-8, Table S4). Differently from previously reported, we did not identify any changes in Lactobacillus spp in any of the groups (data not shown).

To determine whether biological pathways with high sample prevalence rather than specific types of bacteria were associated with hypertension, we then analysed the data using ALDEx2 and PIME, which employs robust machine learning combined with microbiome pathway analysis. 5,984 predicted genes were identified after passing QIIME2-outputted ASV tables through the Pipihillin server. After filtering out low sample prevalence genes using PIME (Figure 2A and 2B) and finding the prevalence interval with the lowest out-of-bag error rate (Figure 2C), only 2,556 genes remained, showing a removal of over 57% of genes from the gene abundance table. In contrast to Figure S3 where at the taxa level we did not see clusters between normotensive and hypertensive groups, at the biological pathway level these groups show distinct clustering (Figure 2D). This supports that while the microbial taxa might be mostly similar between these groups, the gene pathways in each condition are different. There was no clustering between normotensive and masked (Figure 2E) or white coat hypertensive groups (Figure 2F). These findings were also independent of clinic/location, sex, BMI and Australian dietary index scores (Figure S9). We identified 69 microbiome gene pathways that were different as a result of the gut microbiota of hypertensive participants, 31 up-regulated and 38 down-regulated (Table S5). Particularly relevant were the down-regulation of genes involved in the sodium transport system, nitrite transporter and α-galactosidase, all relevant to hypertension and cardiovascular disease (Figure 3A-D).
Moreover, we observed a significant increase in acetate-CoA ligase (ADP-forming) in hypertensive participants (Figure 3E). This enzyme is responsible for the conversion of ATP, acetate and CoA into ADP, phosphate and acetyl-CoA, which is involved in the production of butyrate. This is relevant as acetate and butyrate are abundant SCFAs produced by the gut microbiota, and they are able to lower BP in experimental hypertension.\(^3\)\(^{,\,19}\) No other pathways and genes associated with SCFAs were differentially regulated in human hypertension (Figure S10).

**Short-chain fatty acids and receptors**

To validate these findings, we then directly measured the levels of SCFAs. Hypertensive patients had higher levels of plasma, but not faecal (data not shown, all \(P>0.05\)), total levels of SCFAs compared to normotensive controls (\(P=0.04\), Figure 4A). This was driven by higher levels of acetate (\(P=0.002\), Figure 4B) and butyrate (\(P=0.0008\), Figure 4C), but not propionate (\(P =0.32\), Figure 4D). These associations were still significant after adjustment for age, BMI and sex (acetate: \(\beta= 0.012, P=0.05\); butyrate: \(\beta= 0.519, P=0.006\)). Butyrate levels were positively correlated with 24-hour SBP (\(r=0.428, P=0.0009\), Figure 4E) and DBP (\(r=0.453, P=0.0004\), Figure 4F). We did not see any changes in SCFAs in patients with white coat hypertension, but those with masked hypertension also had higher levels of butyrate (mean±SEM: masked 6.42±0.6 vs others 4.88±0.3, \(P=0.027\)). Changes in plasma and faecal SCFAs were independent of dietary fibre, nut, legume, grain and vegetable intake (data not shown).

These findings, however, were in the opposite direction to what we expected since acetate and butyrate are able to lower BP in experimental hypertension.\(^3\)\(^{,\,19}\) We hypothesised that while hypertensive patients had higher levels of circulating SCFAs, they may lack the receptors that sense SCFAs. We then quantified the mRNA levels of SCFA-sensing
receptors, GPR41, GPR43 and GPR109A, in white blood cells from these patients (Figure 5). We found that hypertensive patients had significantly lower levels of GPR43 (FFAR2) mRNA compared to normotensive controls ($P<0.001$). This was still significant after adjustment for age, BMI and sex ($\beta=-12.3$, $P=0.004$), where only GPR43 expression was still significantly associated with hypertension. GPR43 levels were also strongly negatively correlated with 24-hour SBP ($\rho=-0.75$, $P<0.001$) and DBP ($\rho=-0.70$, $P<0.001$). There were no changes in the expression of GPR41 and GPR019A. Our data suggest that untreated hypertensive patients have elevated circulating levels of acetate and butyrate, but lower levels of the SCFA-sensing receptor GPR43.

**Discussion**

Here we combined machine-learning, gut microbiome sequencing, metabolite and receptor quantification with 24-hour BP monitoring from a multi-centre cohort. Our study uncovered that the gut microbiota of untreated essential, masked and white coat hypertensive subjects is similar to normotensive subjects in terms of diversity and composition, having only minor differences in taxa. It is, however, the gut microbiota-derived gene pathways that are different across groups, particularly between normotensives and essential hypertensives. This was independent of traditional risk factors (e.g., age, sex and BMI) and microbiota risk factors (e.g., location, diet), and some of these changes were detected in the hosts’ circulation. One of the pathways identified involves the production of acetyl-CoA, which is relevant for the production of gut microbiota-derived SCFAs. Indeed, we found that hypertensive participants had higher plasma, but not faecal, levels of acetate and butyrate, but reduced levels of the main receptor that senses these metabolites, GPR43, in immune cells. Taken together, our study uncovered important metabolic gene pathways produced by the human hypertensive
gut microbiota and dysfunction of receptor targets that may drive an increase in BP and could form new therapeutic approaches for hypertension (summarised in Figure 6).

Contrary to some prior studies,4,6,7,9,10 but in accordance with others,8,11-13 we did not observe a change in microbial α diversity between groups. Similarly, most studies have not been able to show a difference9,12 or have not reported differences4,10,13 in microbial β diversity between people with normal and high BP. This may be explained by poor characterisation often with the use of office BP and inclusion of treated patients, amongst other factors.13 Indeed, to date only one study of 54 men recruited in one centre has analysed ABPM.15 Another explanation is the use of BP-lowering medication, which has been associated with changes in the gut microbiota,14,15 as most studied besides one4 combined treated and untreated patients, while others classified treated patients with controlled BP as normotensive controls.6,8 Albeit we did not identify β diversity changes between hypertensive groups, we still identified some differentially prevalent taxa. Particularly relevant are the lower levels of *Ruminococcus* spp. observed in essential hypertensives. *Ruminococcus* spp. are known as SCFA-producers,52 and have been previously associated with hypertension in other cohorts.9,10,12,13 Similarly, the less studied *Acidaminococcus* spp., *Coprobacillus* spp. and *Dialister* spp. have also been reported.4,12

An alternative explanation to the lack of association with microbial diversity and different disease states has been recently introduced: diet may only modify the gut microbiota at the post-transcriptional (proteome) level, leading to altered protein and metabolite production while microbiota composition may remain the same.53 Our study provides the first human evidence that this may be the case for cardiovascular disease, particularly in the setting of untreated essential hypertension diagnosed with ABPM. We show that while α and β diversity remained unchanged, the microbial gene networks associated with hypertension changed dramatically. Particularly relevant to hypertension, we identified that the human
hypertension gut microbiota had higher expression of genes associated with sodium and nitrite transport, α galactosidase and acetate-CoA ligase, all relevant to the development of hypertension, but never before studied from a gut microbiota perspective. The role of intestinal bacteria, as opposed to oral bacteria, to the production of nitric oxide is not known, and was outside the scope of the present study. Similarly, it is still unknown whether bacterial sodium transport activity impacts on the host sodium absorption, but due to the role of the intestine in sodium absorption this could be a new direction to the field. We acknowledge as a limitation of our study that we did not quantify the levels of sodium in the faeces of our participants, because all the material had been used for SCFA and microbiome analyses.

Gut microbial metabolites are key for microbial-host communication. One of the gene pathways we identified was an upregulation of acetate-CoA ligase in hypertensive subjects. Indeed, we found higher levels of acetate and butyrate, another SCFA that can also be a result of down-stream metabolism of acetate by acetate-CoA, in hypertensive subjects. Acetate and butyrate are sensed by three G-protein coupled receptors (GPCR), GPR43 being the major of these receptors. These SCFA-sensing receptors are highly expressed in immune cells, being one of the possible ways that microbiota-host communication takes place. Our study provides the first human evidence that GPR43 is differentially regulated in essential hypertension. One of the major findings of our study is that hypertensive subjects have a significantly lower expression of GPR43. Deficiency of GPR43 signalling results in immune dysfunction which drives a shift to a pro-inflammatory phenotype including recruitment of neutrophils and other immune cells. In a large follow-up study of 28,850 subjects, a greater peripheral neutrophil-to-lymphocyte ratio was found among hypertensive subjects proving inflammation exists in hypertensive subjects and at least involves an increase in neutrophils. Thus, the deficiency of GPR43 signalling may be (partially) responsible for the pro-inflammatory phenotype
(increase in neutrophils) observed in hypertensive subjects. In the future, coupling the immune phenotype of subjects with metabolite-sensing GPCR expression is needed to further understand how SCFA-signalling affects the various immune cells. The increase we observed in SCFAs in hypertensive patients, however, remains unclear. The affinity of SCFA receptors has been shown to vary according to the concentrations of SCFAs, and the decrease in GPR43 could be a compensatory mechanism. This interaction between GPR43 and SCFAs in hypertension likely involves changes in the gastrointestinal tract, which is highly enriched with not only SCFA transporters but also with immune cells that highly express GPR43. Human intestinal tissue combined with colonic and plasma SCFA levels would be ideal to determine their relationship.

We acknowledge our study has some limitations, including the relatively small sample size. Albeit modest, our study took advantage of the only multi-site cohort published to date that has hypertension diagnosed by ABPM and includes both men and women, all untreated for BP-lowering medication. This is also the only cohort to date that contains detailed information regarding dietary intake as well as plasma and faecal metabolites, which allowed us to determine their relationship to the microbiota and BP, and show that our results are robust and valid across 2 independent recruitment sites. As a result of the detailed characterisation of this cohort including ABPM, our sample had similar power to identify microbial associations as some of the largest studies reported to date. However, due to the modest sample size, particularly for the white coat hypertensive group, these results need to be independently validated. Ideally, a meta-analysis should be performed, however, this is impacted by the lack of studies with ABPM data.

In conclusion, we identified that while microbial diversity did not change in essential, masked and white coat hypertension diagnosed with 24-hour BP monitoring, there was a significant shift in microbial gene pathways involved in essential hypertension. Acetate-CoA
ligase was up-regulated, coupled with higher levels of the SCFAs acetate and butyrate.

Hypertensive subjects, however, had lower levels of the SCFA-sensing receptor GPR43 in immune cells, which may blunt their response to BP-lowering metabolites. This suggests that targeting the new pathways and the receptor identified here may aid to control BP in hypertensive patients.

Acknowledgements

We are grateful to Donna Vizi, Vivian Mak and Kaye Carter who assisted with blood collection. We also thank Professor Graham Giles of the Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, for permission to use the Dietary Questionnaire for Epidemiological Studies (Version 3.2), Melbourne: Cancer Council Victoria, 1996.

Sources of Funding

This work was supported by a National Health & Medical Research Council (NHMRC) of Australia Program Grant and fellowship to D.K, fellowship to G.A.H., and a Project Grant to F.Z.M. and D.K. F.Z.M is supported by a National Heart Foundation Future Leader Fellowship and National Heart Foundation Grants. The Baker Heart & Diabetes Institute is supported in part by the Victorian Government's Operational Infrastructure Support Program.

Disclosures

None.
**Author contribution**: conceived and designed the study: FZM. Collected the data: FZM, SY, MC. Performed experiments: FM, MN, PG. Contributed data or analysis tools: FZM, MN, RR, BRS, GAH, PG, SY, MC, JM. Performed analyses: FZM, MN, PG, RR, BRS. Wrote the paper: FZM, MN, RR, RRM. Reviewed the paper: all authors. Secured funding: FZM, DMK.

**Data availability**: The microbiome data underlying this article will be made available at the GenBank Nucleotide Database (under submission at the moment). The other data underlying this article will be shared on reasonable request to the corresponding author.
References


27. Zealand FSAN. Data provided by food companies and organisations. In. Canberra, Australia; 2020.


**Figure legends**

**Figure 1. Gut microbiota taxa linear discriminant analysis effect sizes.**
Gut microbiota taxa that are different between normotensive subjects and A, essential hypertensives (n=46 normotensives and 23 hypertensives), B, masked hypertensives (n=56 normotensives and 13 masked hypertensives), and C, white coat hypertensives (n=65 normotensives and 4 white coat hypertensives) with a linear discriminant analysis (LDA) score of least 2.

**Figure 2. Machine-learning de-noised prevalence filtered gene data.**
A. Using the DADA2/PIME/ALDEx2 machine-learning pipeline described in Methods, the initial microbiome ASV dataset of 5,488 total raw data pathways was parsed into 5% intervals and ranked by out-of-bag (OOB) errors of signal-to-noise ratios giving minimized OOB error rate = 0 at the 85% prevalence level. This interval held 2,556 gene pathways. B. Mann-Whitney plot validating the 2,556 prevalent pathways (red points) of the 85% prevalence interval of (A). These pathways were subsequently used downstream for all the ensuing multivariate analyses comparing the groups. Points represent unique microbial gene functions that are differentially abundant at q<0.1 (red); abundant but non-differentially abundant (gray); rare and not differentially abundant (black). C. Principal component analysis (PCA) of prevalent microbial gene pathways using the data pool of (A) and (B), comparing essential hypertensive subjects (n=20) vs. normotensives (n=45). D. PCA comparing masked hypertensives (n=12) vs. normotensives (n=53). E. PCA comparing white coat hypertensives (n=4) vs. normotensives (n=61). All PCA points are shown within 95% confidence interval ellipses.

**Figure 3. Microbial metabolic pathways that were differentially expressed between normotensive and essential hypertensive subjects, shown as gene counts.** A, Sodium transport
system permease protein 1, and B, ATP binding protein 1, C, nitrite transporter 1, D, α-galactosidase 2, and E, acetate-CoA ligase (ADP-forming) α-subunit 1. See Table S5 for more information. Showing mean ± standard error of mean. Sample size: n=43 normotensives and n=22 hypertensives. ***indicates \( P<0.001 \).

**Figure 4.** Plasma levels of gut microbial metabolites short-chain fatty acids (SCFAs) in association with hypertension. Showing A, total SCFAs, B, acetate, C, butyrate, and D, propionate. Showing mean ± standard error of mean. Correlations between butyrate and E, systolic blood pressure (SBP) and F, diastolic blood pressure (DBP). *indicates \( P<0.05 \), ***\( P <0.001 \).

**Figure 5.** Relative expression of short-chain fatty acids (SCFAs)-sensing receptors, showing that A, GPR43 mRNA is down-regulated in white blood cells of hypertensive participants, while there are no changes in B, GPR41 and C, GPR109A. Showing mean ± standard error of mean. Sample size: n=25 normotensives and 22 hypertensives. ***indicates \( P<0.001 \).

**Figure 6.** Summary of the study findings.
## Tables

### Table 1. Demographics and clinical characteristics of participants.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Normotensives</th>
<th>Hypertensives*</th>
<th>White coat hypertensives</th>
<th>Masked hypertensives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size (n, %)</td>
<td>47 (67%)</td>
<td>23 (33%)</td>
<td>4 (6%)</td>
<td>13 (19%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>59.2±7.7</td>
<td>60.3±6.6</td>
<td>60.0±9.8</td>
<td>59.1±7.5</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.9±3.0</td>
<td>26.0±2.6</td>
<td>23.9±1.3</td>
<td>26.6±2.3</td>
</tr>
<tr>
<td>Waist to hip ratio</td>
<td>0.86±0.1</td>
<td>0.88±0.1</td>
<td>0.85±0.1</td>
<td>0.88±0.01</td>
</tr>
<tr>
<td>Sex (% female)</td>
<td>31 (66%)</td>
<td>8 (35%)†</td>
<td>1 (25%)</td>
<td>4 (31%)†</td>
</tr>
<tr>
<td>Office SBP (mmHg)</td>
<td>122.3±12.5</td>
<td>135.6±18.0‡</td>
<td>140.9±9.9§</td>
<td>123.1±12.5</td>
</tr>
<tr>
<td>Office DBP (mmHg)</td>
<td>75.5±8.3</td>
<td>82.2±10.5‡</td>
<td>89.3±6.0§</td>
<td>76.3±8.8</td>
</tr>
<tr>
<td>24h SBP (mmHg)</td>
<td>114.3±8.5</td>
<td>139.7±10.1§</td>
<td>120.0±5.3</td>
<td>135.2±7.6§</td>
</tr>
<tr>
<td>24h DBP (mmHg)</td>
<td>69.6±5.1</td>
<td>83.1±6.3§</td>
<td>74.0±8.6†</td>
<td>80.4±5.1§</td>
</tr>
<tr>
<td>Day SBP (mmHg)</td>
<td>121.8±9.5</td>
<td>145.7±9.8§</td>
<td>127.8±2.1</td>
<td>141.3±7.8§</td>
</tr>
<tr>
<td>Day DBP (mmHg)</td>
<td>75.5±6.2</td>
<td>87.6±5.9§</td>
<td>80.9±4.9</td>
<td>84.8±4.4§</td>
</tr>
<tr>
<td>Night SBP (mmHg)</td>
<td>105.3±8.7</td>
<td>132.3±12.3§</td>
<td>110.2±9.4</td>
<td>127.5±10.0§</td>
</tr>
<tr>
<td>Night DBP (mmHg)</td>
<td>62.6±5.1</td>
<td>77.4±8.4§</td>
<td>67.1±3.0</td>
<td>74.6±7.4§</td>
</tr>
</tbody>
</table>

Data are shown as mean ± standard deviation or numbers and percentages. Legend: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WHR, waist to hip ratio. *Hypertensives include essential hypertensives and masked hypertensives. Significant associations in bold. †P<0.05, ‡P<0.01, §P<0.001.
Figures

Figure 1
Figure 5

A  
GPR43 (FFAR2) mRNA

B  
GPR41 (FFAR3) mRNA

C  
GPR109A (HCAR2) mRNA

relative expression

Normotensives  Hypertensives

***
Figure 6